FibroGen and Regeneron Pharmaceuticals forge clinical trial collaboration for cancer treatment
FibroGen, Inc. (NASDAQ: FGEN) has entered into a clinical trial supply agreement with Regeneron Pharmaceuticals, aiming to evaluate FibroGen’s immuno-oncology assets, FG-3165 and FG-3175, in ... Read More
Breakthrough in colorectal cancer as Regeneron Pharmaceuticals reveals promising results from immunotherapy trial
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has announced encouraging early outcomes from its Phase 1/2 clinical trial, which evaluates a new immunotherapy combination of REGN7075 and ... Read More
Sanofi, Regeneron get Dupixent EC approval for eosinophilic esophagitis
French pharmaceutical company Sanofi and Regeneron, an American biotechnology company, have received the approval of the European Commission (EC) to market their Dupixent (dupilumab) injection ... Read More
Regeneron gets Libtayo approval in Japan for advanced cervical cancer
Regeneron Pharmaceuticals has secured the approval of the Japanese Ministry of Health, Labor and Welfare (MHLW) to manufacture and market the company’s Libtayo (cemiplimab) for ... Read More
Regeneron says REGEN-COV monoclonal antibodies active against Omicron, Delta and other variants
Regeneron Pharmaceuticals said that the monoclonal antibodies of its REGEN-COV cocktail are active against all known variants of concern of Covid-19, including Omicron and Delta. ... Read More
Roche, Cipla to bring Casirivimab/Imdevimab Covid-19 drug to India
Roche India said that India’s Central Drugs Standards Control Organisation (CDSCO) has granted an emergency use authorisation (EUA) for the Casirivimab, Imdevimab antibody cocktail for ... Read More
Regeneron Pharmaceuticals’ Inmazeb FDA approval: A milestone in Ebola treatment
Regeneron Pharmaceuticals has achieved a significant breakthrough with the approval of its antibody cocktail, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), by the U.S. Food and Drug ... Read More
Regeneron Pharmaceuticals begins COVID-19 clinical trials of REGN-COV2
US biotech company Regeneron Pharmaceuticals has started the first clinical trial of its investigational dual antibody cocktail REGN-COV2 (REGN10933+REGN10987) for the prevention and treatment of ... Read More
Dupixent delivers positive results in eosinophilic esophagitis trial
Regeneron Pharmaceuticals and Sanofi said that their co-developed eczema drug Dupixent (dupilumab) has met the co-primary endpoints of Part A of a phase 3 trial ... Read More
Sanofi, Regeneron secure Libtayo EMA approval for a type of skin cancer
Libtayo EMA approval : The European Commission has given conditional approval for Libtayo (cemiplimab) for the treatment of adult patients with metastatic or locally advanced ... Read More